Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Latest Content

Arrowhead doses first patient in Phase I/II trial of ARO-HSD

US-based biopharmaceutical firm Arrowhead Pharmaceuticals has started dosing subjects in a Phase I/II clinical trial (AROHSD1001) of ARO-HSD for the treatment of patients suffering from alcohol and non-alcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Close
Close
Close

Go Top